CAS Case Digest · Verified against the full award text

CAS 2025/A/11839 — World Anti-Doping Agency (WADA) v. Anti-Doping Agency of Kenya (ADAK) & Edwin Kipkemoi Seko

"Seko" · CAS increased a Kenyan long-distance runner's 16-month ban to 4 years and 6 months for intentional testosterone use and evasion of sample collection.

What happened in Seko

Edwin Kipkemoi Seko, a Kenyan national-level long-distance runner, committed two anti-doping rule violations: (i) Use of a Prohibited Substance (testosterone via a declared 'Sustanon injection') under Article 2.2 ADAK ADR, and (ii) Evasion/Failure to Submit to Sample Collection under Article 2.3 ADAK ADR, when he boarded a motorcycle and fled the competition venue on 22 May 2024 after signing the doping control form. Kenya's Sports Disputes Tribunal found both violations but imposed only 16 months' ineligibility, concluding that neither violation was intentional. WADA appealed to CAS. The Sole Arbitrator found that the Athlete failed to rebut the presumption of intentional use under Article 10.2.3 ADAK ADR, applying the doctrine of indirect intent: even accepting an emergency hospitalisation, the Athlete took no steps to verify whether administered substances were prohibited. The Arbitrator also reclassified the Article 2.3 ADRV as Evasion rather than mere Failure to Submit, making fault-based reductions unavailable. Aggravating Circumstances were found due to two independent ADRVs and the Athlete's lack of credibility. The sanction was set at 4 years and 6 months commencing 11 August 2024. The case matters because it confirms that post-use verification duties apply even after emergency medical treatment, and that an evolving, uncorroborated factual account cannot rebut the presumption of intent.

Procedural history of CAS 2025/A/11839

On 21 May 2024, the Athlete declared use of a 'Sustanon injection' on his doping control form at the Athletics Kenya National Championship. On 22 May 2024, he fled the competition venue on a motorcycle after signing the Second Doping Control Form, constituting an Article 2.3 ADRV. ADAK provisionally suspended the Athlete from 11 August 2024. ADAK filed charge documents seeking 4 years (Article 2.3) and 8 years (Article 2.2) of ineligibility; at written submissions stage ADAK sought 6 years. The Sports Disputes Tribunal of Kenya held hearings on 30 January, 13 February, and 28 February 2025, and on 15 May 2025 imposed only 16 months' ineligibility, finding neither violation intentional. WADA received the Appealed Decision on 24 August 2025 and the case file on 23 September 2025. WADA filed its Statement of Appeal with CAS on 14 October 2025, within the 21-day deadline under Article 13.6.1 ADAK ADR. A videoconference hearing was held on 4 March 2026.

Key holdings in CAS 2025/A/11839

• An athlete who fails to take any steps after an emergency hospitalisation to verify whether administered medications contain prohibited substances acts with indirect intent under Article 10.2.3 ADAK ADR and cannot rebut the presumption of intentional use.
• An evolving, uncorroborated factual account — particularly one in which material new facts (such as unconsciousness) are raised for the first time on appeal — cannot satisfy the balance-of-probability standard required to rebut the presumption of intent.
• Where an athlete signs a doping control form, is aware of the testing requirement, and then boards a motorcycle to flee the venue, the conduct constitutes Evasion under Article 2.3 ADAK ADR, not merely Failure to Submit, making fault-based reductions unavailable.
• Two entirely separate and independent ADRVs (Use and Evasion) constitute Aggravating Circumstances under Article 10.4 ADAK ADR, justifying an increase to the standard 4-year period of ineligibility.
• Where delays in the hearing process are attributable to the first-instance body's erroneous application of the law rather than to the athlete, Article 10.13.1 ADAK ADR permits the period of ineligibility to commence from the date of provisional suspension rather than the date of the CAS award.

How the CAS panel reasoned

The Sole Arbitrator conducted a de novo review under Article R57 CAS Code. On the Article 2.2 ADRV, she accepted for the Athlete's benefit that medication may have been administered in an emergency, but held that a post-use duty of investigation exists regardless: an athlete who knows he received medication in hospital and takes no steps to check for prohibited substances 'runs into a minefield ignoring all stop signs' (citing CAS 2012/A/2822). The Athlete's credibility was fatally undermined by the late introduction of the unconsciousness narrative — absent from all prior statements and unsupported by medical records — and by demonstrably false statements about his competitive history and prior testing. On the Article 2.3 ADRV, the Arbitrator applied the definition of 'evading' from CAS 2021/A/7998 and CAS 2023/A/9568, finding that the Athlete's own handwritten account confirmed deliberate flight. The alleged 'not normal frame of mind' was unsupported by any medical evidence. On Aggravating Circumstances, the Arbitrator weighed the two independent ADRVs and the Athlete's persistent lack of credibility against the mitigating factor that both violations occurred on consecutive days during a period of apparent post-hospitalisation vulnerability, ultimately adding six months to the standard 4-year sanction. The backdating of the sanction to 11 August 2024 was justified because the SDT's legal errors — not the Athlete's conduct — caused the delay.

Why Seko matters in CAS jurisprudence

Seko reinforces that the duty to verify medications for prohibited substances survives even a genuine medical emergency — the obligation shifts to a post-use investigation duty. It also clarifies the evasion/failure-to-submit distinction under the 2021 WADC framework, confirming that signing a doping control form and then fleeing constitutes evasion, foreclosing fault-based reductions. The case further illustrates CAS's willingness to apply Article 10.13.1 to protect athletes from the consequences of first-instance bodies' legal errors, while still imposing the correct, higher sanction.

Cases cited in this award

CAS 2016/A/4609 CAS 2012/A/2822 CAS 2021/A/7983 & CAS 2021/A/8059 CAS 2021/A/7998 CAS 2023/A/9568

Frequently asked questions about Seko

Why did CAS increase Seko's ban from 16 months to 4 years and 6 months?

The Sole Arbitrator found that the SDT had wrongly concluded neither violation was intentional. For the testosterone use, the Athlete failed to rebut the presumption of intent because he took no steps after his hospitalisation to check whether administered substances were prohibited. For the sample collection violation, the conduct was reclassified as Evasion — not mere Failure to Submit — because the Athlete signed the doping control form and then fled on a motorcycle. Aggravating Circumstances (two independent ADRVs) added a further six months to the standard 4-year sanction.

Does the Seko case mean an athlete cannot rely on emergency medical treatment to avoid an intentional doping finding?

Not automatically. The Sole Arbitrator accepted for the Athlete's benefit that medication may have been administered in an emergency, but held that a post-use duty of investigation still exists: an athlete who knows he received medication in hospital and takes no steps to verify whether it contained prohibited substances acts with indirect intent under Article 10.2.3 ADAK ADR. The Athlete's credibility was also fatally undermined by the late introduction of an unconsciousness narrative unsupported by medical records.

What is the difference between evasion and failure to submit under the ADAK ADR, and why did it matter in Seko?

Under Article 10.3.1 ADAK ADR, a non-intentional Failure to Submit can be reduced to a 2-year ban, whereas Evasion can only be reduced (to a range of 2–4 years) upon proof of 'exceptional circumstances'. The Sole Arbitrator found that the Athlete's conduct — signing the doping control form, requesting permission to leave, and then boarding a motorcycle to flee — met the definition of Evasion from CAS 2021/A/7998 and CAS 2023/A/9568, so the lower fault-based reduction was unavailable and the standard 4-year sanction applied.

Why did the Seko ban start on 11 August 2024 rather than the date of the CAS award?

Under Article 10.13.1 ADAK ADR, where substantial delays in the hearing process are not attributable to the athlete, the period of ineligibility may start as early as the date of sample collection. The Sole Arbitrator found that the SDT's blatantly erroneous application of the law — not any conduct by the Athlete — caused the delay, and that it would be unfair for the Athlete to serve effectively almost five and a half years of effective competitive exclusion. The ban was therefore backdated to 11 August 2024, the first day of the provisional suspension imposed by ADAK.

Topics: Doping, ethics & governance at CAS

Source: official award. This digest was generated by LexXi from the full award text and machine-verified against it — every figure, article and citation above appears in the source. It is an editorial summary, not legal advice. See how ElevenLex verification works.